ArticleACS sensors2021
β-Sheet Richness of the Circulating Tumor-Derived Extracellular Vesicles for Noninvasive Pancreatic Cancer Screening.
Article in ACS sensors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Isolation and characterization of extracellular vesicles from human milk for potential use as a dietary supplement in clinical research with preterm infants.Frontiers in nutrition · 2026Article
- Automating the amino acid identification in elliptical dichroism spectrometer with Machine Learning.PloS one · 2025Article
- Targeting emerging amino acid dependencies and transporters in cancer therapy.Frontiers in pharmacology · 2025Review
- Characterizing biomolecular structure features through an innovative elliptical dichroism spectrometry for cancer detection.Heliyon · 2024Article
- Integrated proteomic profiling identifies amino acids selectively cytotoxic to pancreatic cancer cells.Innovation (Cambridge (Mass.)) · 2024Article
- Label-Free, Noninvasive Bone Cell Classification by Hyperspectral Confocal Raman Microscopy.Chemical & biomedical imaging · 2024Article
- Variabilities in global DNA methylation and β-sheet richness establish spectroscopic landscapes among subtypes of pancreatic cancer.European journal of nuclear medicine and molecular imaging · 2023Article
- A portable elliptical dichroism spectrometer targeting secondary structural features of tumorous protein for pancreatic cancer detection.Biosensors & bioelectronics · 2023Article
- The Convergence of FTIR and EVs: Emergence Strategy for Non-Invasive Cancer Markers Discovery.Diagnostics (Basel, Switzerland) · 2022Review
- Environmental noise reduction for tunable resistive pulse sensing of extracellular vesicles.Sensors and actuators. A, Physical · 2022Article
- Article
- Microfluidic Approaches for Affinity-Based Exosome Separation.International journal of molecular sciences · 2022Review
- Recent advances in optical label-free characterization of extracellular vesicles.Nanophotonics (Berlin, Germany) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Tumor-derived extracellular vesicles (EVs) are under intensive study for their potential as noninvasive diagnosis biomarkers. Most EV-based cancer diagnostic assays trace supernumerary of a single cancer-associated marker or marker signatures. These types of biomarker assays are either subtype-specific or vulnerable to be masked by high background signals. In this study, we introduce using the β-sheet richness (BR) of the tumor-derived EVs as an effective way to discriminate EVs originating from malignant and nonmalignant cells, where EV contents are evaluated as a collective attribute rather than single factors. Circular dichroism, Fourier transform infrared spectroscopy, fluorescence staining assays, and a de novo workflow combining proteomics, bioinformatics, and protein folding simulations were employed to validate the collective attribute at both cellular and EV levels. Based on the BR of the tumorous EVs, we integrated immunoprecipitation and fluorescence labeling targeting the circulating tumor-derived EVs in serum and developed the process into a clinical assay, named EvIPThT. The assay can distinguish patients with and without malignant disease in a pilot cohort, with weak correlations to prognosis biomarkers, suggesting the potential for a cancer screening panel with existing prognostic biomarkers to improve overall performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.